PepGen Stock: Maintaining 'Hold' PGN-EDODM1 Data Is Major Inflection Point (NASDAQ:PEPG)
· seekingalpha.com
PepGen stays a hold, after a major problem with its released data from the phase 2 FREEDOM2-DM1 study using the PGN-EDODM1 study. Read more on PEPG stock here.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...